Allergan today (23/1/13) said that it would buy US based MAP Pharmaceuticals in a $958m acquisition. Allergan is purchasing MAP Pharmaceuticals in cash and has paid a 60% premium on the closing share price of MAP. Allergan expects the deal to dilute 2013 earnings by about 7 cents a share and begin to add revenue in H2 2014. The purchase follows on from a collaboration agreement Allergan and MAP made in January 2011 to co-promote Levadex in the US and Canada.
On the 27th December 2012, Parexel announced they had completed the purchase of Regulatory Submissions experts Liquent for $72m from Marlin Equity Partners. Liquent is a global provider of Regulatory Information Management solutions to more than 200 biopharmaceutical and life science companies across the globe. Liquent currently have offices based in Pennsylvania (Headquaters), UK, Germany and India. Liquent currently employ nearly 300 staff.